BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl
FDA Approves Drug’s Third US Indication And Its Biggest Yet
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
